Clinical trial · Observational
Effect of Gastrectomy and Anastomosis on Diabetes and Hypertension in Early Gastric Cancer Patients
Effect of Gastrectomy and Anastomosis on Chronic Metabolic Disease Such as Diabetes and Hypertension in Early Gastric Cancer Patients
NCT01643811CI-TRIAL-00021491completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether the extent of gastrectomy and anastomosis type affect chronic metabolic disease such as diabetes and hypertension in early gastric cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Early Gastric Cancer | Early Gastric Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endoscopic submucosal dissection | Procedure | — | UNRESOLVED |
| gastrectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Gastrectomy
- description
- Patients who underwent gastrectomy for early gastric cancer
- interventionNames
- Procedure: gastrectomy
- label
- Endoscopic submucosal dissection
- description
- Patients who underwent endoscopic submucosal dissection for early gastric cancer
- interventionNames
- Procedure: Endoscopic submucosal dissection
Primary outcomes (2)
- measure
- Proportion of patients who quit previous medication for diabetes because of improved disease
- timeFrame
- 5 year after operation
- description
- proportion of patients who quit their previous medication for diabetes because of improved disease after operation among all patients who underwent gastrectomy for early gastric cancer with diabetes.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven primary gastric adenocarcinoma * clinical stage Ia or Ib examined with endoscopy, endoscopic ultrasound, and computed tomography * aged 20-80 year old, * performance status (PS) of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale * diagnosed as diabetes or hypertension * patients planning to undergo gastrectomy or endoscopic submucosal dissection * written informed consent Exclusion Criteria: * having high risk for operation such as severe heart disease, severe respiratory disease * pregnant * previous abdominal surgery or radiation therapy * proven more advanced disease than pathological stage II requiring adjuvant chemotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.